Business Wire

Business Wire, a wholly owned subsidiary of Berkshire Hathaway, is the global market leader in commercial news distribution.

Recent Articles By The Author

Partner Communications Announces The Early Repayment Of Loans

Partner Communications Company Ltd. ("Partner" or the "Company") (NASDAQ:PTNR)(TASE:PTNR), a leading Israeli communications operator, announced today that it has executed early repayments of 4 loans (loans C, D, E and F)...

WPP Makes It A Magnificent Seven In Cannes

For the seventh year in succession, WPP (NASDAQ:WPPGY) has been named the world's most creative parent company at the Cannes Lions International Festival of Creativity.

Ra Pharmaceuticals Presents Data On Oral Small Molecule Complement Inhibitors At The 22nd Congress Of The European Hematology Association

Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement mediated diseases, today announced the...

Verastem Reports Phase 2 Long-Term Follow-Up Data For Duvelisib In Patients With Double-Refractory Follicular Lymphoma And Small Lymphocytic Lymphoma At The 22nd Congress Of The European Hematology Association

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the presentation of long-term follow-up data from the DYNAMO™...

Four-Year Follow-up With Empliciti (elotuzumab) Plus Lenalidomide/Dexamethasone (ELd) In Patients With Advanced Multiple Myeloma Shows Long-term Efficacy In ELOQUENT-2 Trial

Bristol-Myers Squibb Company (NYSE:BMY) presented four-year follow-up data from the Phase 3 ELOQUENT-2 study in which Empliciti (elotuzumab) plus lenalidomide/dexamethasone (ELd) continued to demonstrate efficacy in...